Vor Biopharma Inc (VOR) Q1 2026 Earnings Report

Vor Biopharma reported QQ1 2026 results with no revenue and a noticeable tilt toward non-operating charges, resulting in a net loss of $219.585 million and an EPS of -$5.11 for the quarter ended March 31, 2026. Operating expenses totaled $35.16 million, comprised of $17.60 million in R&D and $17.56 million in G&A, underscoring the company’s clinical-stage burn as it advances VOR33 (an engineered hematopoietic stem cell therapy targeting AML and other hematologic malignancies). A dominant line item in the quarter was total other income/expenses of -$184.425 million, which dwarfed the operating loss and suggests material non-operating charges or non-cash items that significantly affected reported profitability.

Year-over-year and quarter-over-quarter metrics reflect a stark deterioration in profitability: operating income declined by -8.77% YoY and -5.61% QoQ, while net income plunged by -612.85% YoY and -575.94% QoQ. The reported earnings per share deteriorated by -1,035.56% YoY and -1,865.38% QoQ. The data indicates a company still in the early stage of its development trajectory, heavily reliant on capital markets or strategic partnerships to fund ongoing R&D and corporate costs while awaiting clinical readouts from its VOR33 program. Management commentary (where available) is not included in the provided data; consequently, the quarter’s profitability dynamics appear driven primarily by R&D investment and sizable non-operating charges rather than commercial execution.

Investors should monitor liquidity runway, potential financing activities, and milestones for VOR33 readouts, as these will be pivotal for determining the sustainability of current operating losses and the likelihood of de-risking the business through clinical data announcements or strategic collaborations.